A5058497646- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Implant and Reconstruction
- Hair Growth and Disorders
- T-cell and Retrovirus Studies
- Breast Cancer Treatment Studies
- Women's cancer prevention and management
- Estrogen and related hormone effects
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Multiple Sclerosis Research Studies
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Advanced Breast Cancer Therapies
- Bone health and osteoporosis research
- SARS-CoV-2 and COVID-19 Research
- Chronic Myeloid Leukemia Treatments
- Breast Lesions and Carcinomas
- Orthopedic Infections and Treatments
- Bone health and treatments
- Brain Metastases and Treatment
- Herpesvirus Infections and Treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Bone fractures and treatments
- Global Cancer Incidence and Screening
Mayo Clinic
2024
Mayo Clinic in Arizona
2024
WinnMed
2024
Baylor College of Medicine
2021-2022
Augusta University
2019-2021
Florida College
2019
James A. Haley Veterans' Hospital
2019
University of Florida
2019
Abstract Introduction. T-DXd is FDA-approved for patients (pts) with hormone receptor positive (HR+) or HR- HER2-low (IHC 1+ 2+, ISH-) MBC and SG pts HR+/HER2- triple negative MBC. However, several outstanding questions impact the use of these drugs in clinic, including: 1) what efficacy safety agents real-world populations diverse pt characteristics not well represented pivotal phase III trials, 2) sequential treatment ADCs on agents. Methods. In this multicenter retrospective cohort study,...
Prior to the advent of HER2-targeted monoclonal antibody trastuzumab, HER2+ breast cancer (BC) was considered an aggressive disease with a poor prognosis. Over past 25 years, innovations in molecular biology, pathology, and early therapeutics have transformed treatment landscape. With multiple HER2-directed therapies, there been immense improvements oncological outcomes both adjuvant metastatic settings. Currently, 8 therapies are approved by Food Drug Administration (FDA) for early-stage...
1083 Background: T-DXd and SG are both FDA-approved treatments for patients (pts) with HER2-low MBC, but little data exists on the sequential use of these ADCs. Methods: In this multicenter retrospective cohort study, we identified pts MBC treated sequentially in either order, or without intervening therapies (IntTx), at 5 academic centers between 2020-2023. We previously reported real-world progression free survival (rwPFS) overall (rwOS) by HR-status ADC sequence order. Here provide...
11145 Background: T-DXd is increasingly used in mBC. A toxicity of special interest interstitial lung disease/pneumonitis (ILD), occurring 10-15% pts the DESTINY-Breast trials, and with potential lower incidence/severity earlier line settings [Krop et al, ASCO 2023]. However, routine practice, may be more heavily pre-treated mBC previously exposed to other antibody-drug conjugates (ADC) [Premji al SABCS We evaluated related ILD at Mayo Clinic. Methods: retrospectively identified who received...
636 Background: Musculoskeletal symptoms, for which there is no standard therapy, are common in women on aromatase inhibitors (AIs) PEBC. A phase III randomized study explored whether exercise improves arthralgias / myalgias (A/M). Methods: Eligible with EPBC had A/M related to and were an (E) or a control (C) group. E patients exercised 3x weekly 48 weeks; the first 12 weeks supervised setting; second weeks, once twice independently, last 24 using aerobic resistance programs tailored their...
Introduction. Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare disease entity associated with textured breast implants. Though the clinical course typically indolent, BIA-ALCL can occasionally invade through capsule into parenchyma spread to regional lymph nodes and beyond including chest wall invasive disease. Case. We present case of 51-year-old female history bilateral silicone implants placed approximately twenty years ago who presented two months...
Multifocal necrotizing leukoencephalopathy (MNL) is a rare condition typically described in patients undergoing chemotherapy or with HIV/AIDS. As pathologic entity, it characterized by multiple small foci of necrosis within white matter the pons and occasionally other areas. Herein we describe findings 6 MNL, 5 diagnosed at postmortem examination 1 surgical biopsy. Histopathologic features were characteristic, generally necrosis, most frequently pontine base, although larger lesions seen...
We used Veterans Health Administration (VHA) national administrative data files to identify a cohort (fiscal years 2005-2014) of veterans with spinal cord injuries and disorders (SCID) determine risk factors for consequences lower extremity fracture nonunions. Odds ratios (OR) nonunion were computed using multivariable-adjusted logistic regression models. identified three nonunion: (i) older age (OR = 2.29; 95% confidence interval [CI] 1.21-4.33), (ii) longer duration SCID 1.02; CI...
Abstract Introduction: Interstitial Lung Disease (ILD) is a known adverse event associated with Antibody Drug Conjugates (ADCs), causing fibrosis of the lung. In DESTINY-Breast 04, TROPICS-02, and ASCENT trials rate ILD/Pneumonitis was 12.1%, 0.4%, 0% respectively. these studies, time to first cross-sectional imaging after initiation ADC 6 weeks. However, prior treatment topoisomerase-1 inhibitor not permitted in so influence sequential treatments remains unknown. Here, we aimed characterize...
Abstract Background: Eyebrow and eyelash loss, known as madarosis, can occur secondary to breast cancer-directed therapy. However, the incidence predictors of this phenomenon are not well-known. The purpose study is ascertain proportion cancer survivors who experience potential contributing factors eyebrow associations between symptom mental health. Methods: Breast were invited participate in an ongoing longitudinal cohort study, Mayo Clinic Disease Registry (MCBDR), after having been seen...
Abstract Background: Retrospective studies suggest that breast cancer survivors report treatment-associated hair loss or thinning years after their initial diagnosis. This study investigates patient perceptions of alopecia persisting 6 the diagnosis cancer. Methods: Breast who had signed informed consent for participation in a prospective longitudinal cohort study, Mayo Clinic Disease Registry (MCBDR), approximately six prior, were mailed survey. survey asked about degree bother from and on...
10507 Background: In the recent decade, novel therapies have led to significant improvements in overall survival (OS) symptomatic multiple myeloma (MM). With this increase OS, there is an incidence of second primary malignancies (SPM) patients with MM. This related factors; we hypothesize that racial disparities also play a role. There paucity studies large, high quality datasets evaluating SPMs Our goal explore patterns US Veterans MM, focusing on disparities. Methods: We conducted...
Abstract We present a case of 58‐year‐old male patient who presented to his primary care clinic with complaints eye swelling and fatigue. Workup ultimately led diagnosis AL amyloidosis secondary myeloma based on SLiM‐CRAB criteria. discuss diagnostic workup, treatment, subsequent relapse.
e13067 Background: Recently, next generation sequencing (NGS) has been used with increasing frequency to guide therapy decisions for patients metastatic solid tumors. NGS is a DNA technology that detects somatically acquired mutations. If an actionable mutation identified, it may affect prognosis and therapy. At our institution we serve large proportion of minority underserved analyzed their results determine if there was change in management. Methods: Patients breast cancer treated at one...